Q1 2026 Earnings Forecast for Theravance Biopharma, Inc. (NASDAQ:TBPH) Issued By Zacks Research

Theravance Biopharma, Inc. (NASDAQ:TBPH) – Research analysts at Zacks Research increased their Q1 2026 earnings per share estimates for shares of Theravance Biopharma in a report issued on Monday, April 15th. Zacks Research analyst K. Shah now forecasts that the biopharmaceutical company will earn $0.29 per share for the quarter, up from their prior forecast of $0.25. The consensus estimate for Theravance Biopharma’s current full-year earnings is ($0.83) per share.

A number of other brokerages have also recently commented on TBPH. BTIG Research started coverage on Theravance Biopharma in a research note on Friday, April 12th. They issued a “buy” rating and a $21.00 price target for the company. Evercore ISI lowered Theravance Biopharma from an “outperform” rating to an “inline” rating in a research report on Monday, January 8th.

Theravance Biopharma Price Performance

Shares of TBPH stock opened at $9.52 on Tuesday. The stock has a market cap of $462.29 million, a PE ratio of -9.81 and a beta of 0.36. The stock has a 50-day moving average of $8.98 and a 200-day moving average of $9.66. Theravance Biopharma has a one year low of $8.21 and a one year high of $11.98.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). The company had revenue of $17.57 million during the quarter, compared to the consensus estimate of $17.49 million. Theravance Biopharma had a negative net margin of 96.12% and a negative return on equity of 19.31%.

Hedge Funds Weigh In On Theravance Biopharma

Institutional investors and hedge funds have recently modified their holdings of the business. Bank of America Corp DE boosted its position in Theravance Biopharma by 102.4% during the 1st quarter. Bank of America Corp DE now owns 1,775,966 shares of the biopharmaceutical company’s stock worth $19,269,000 after acquiring an additional 898,691 shares during the last quarter. Two Sigma Advisers LP acquired a new position in Theravance Biopharma during the 3rd quarter worth approximately $7,064,000. Two Sigma Investments LP acquired a new position in Theravance Biopharma during the 3rd quarter worth approximately $6,620,000. Vanguard Group Inc. boosted its position in Theravance Biopharma by 10.3% during the 1st quarter. Vanguard Group Inc. now owns 6,947,947 shares of the biopharmaceutical company’s stock worth $66,421,000 after acquiring an additional 648,124 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its position in Theravance Biopharma by 184.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 976,373 shares of the biopharmaceutical company’s stock worth $9,335,000 after acquiring an additional 632,582 shares during the last quarter. 99.10% of the stock is currently owned by institutional investors and hedge funds.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.